We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma.
- Authors
HARDY, Juliette; BORALEVI, Franck; MALLET, Stéphanie; CABRERA, Natalia; BELOT, Alexandre; PHAN, Alice; BARBAROT, Sébastien; DURIEZ-LASEK, Audrey; CHIAVERINI, Christine; HUBICHE, Thomas; MAHE, Emmanuel; BEGON, Edouard; BOURRAT, Emmanuelle; BOCCARA, Olivia; AUBERT, Hélène; LEROSEY, Martine GRALL; DROITCOURT, Catherine; PIRAM, Maryam; MAZEREEUW-HAUTIER, Juliette
- Abstract
Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Methotrexate dosage ranged from 7 to 15 mg/m²/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho trexate and we did not identify a clinical profile for those resistant patients.
- Subjects
THERAPEUTICS; DRUG dosage; METHOTREXATE
- Publication
Acta Dermato-Venereologica, 2019, Vol 99, Issue 6, p539
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-3155